Brief: Oragenics Initiates COVID-19 Challenge Study Testing Multiple Formulations Of Its Vaccine Candidate
15/09/2021 12:35
Sept 15 (Reuters) - Oragenics Inc OGEN.A :
* ORAGENICS INITIATES COVID-19 CHALLENGE STUDY EVALUATING
MULTIPLE
FORMULATIONS OF ITS SARS-COV-2 VACCINE CANDIDATE
* ORAGENICS INC - INTRANASAL AND INTRAMUSCULAR FORMULATIONS
TO BE
ASSESSED WITH NOVEL ADJUVANTS
Source text for Eikon: ID:nBw42jR3Va
Further company coverage: OGEN.A
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Oragenics
See all newsBrief: Oragenics Reports Continued Clinical Progress, Provides Regulatory And NYSE American Listing Update
Brief: Oragenics Signs Letter Of Intent To License Cardiodialysis™ Technology From Sigyn Therapeutics To Target Tbi-Induced Systemic Inflammation
Brief: Oragenics Inc - Signs Letter Of Intent To License Cardiodialysis From Sigyn Therapeutics - SEC Filing
Brief: Oragenics Activates Second Site In Phase Iia Clinical Trial Of Onp-002 For Concussion And Mild Traumatic Brain Injury.
Brief: Oragenics Enters Settlement Agreement With Ladenburg Thalmann - Sec Filing